Theresa Heggie - 13 Aug 2025 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role
Director
Signature
/s/ Alane P. Barnes, by power of attorney
Issuer symbol
BCRX
Transactions as of
13 Aug 2025
Net transactions value
-$292,168
Form type
4
Filing time
15 Aug 2025, 08:24:54 UTC
Previous filing
16 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
HEGGIE THERESA Director 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM /s/ Alane P. Barnes, by power of attorney 15 Aug 2025 0001760020

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCRX Common Stock Options Exercise $87,300 +30,000 +46% $2.91 95,352 13 Aug 2025 Direct
transaction BCRX Common Stock Options Exercise $216,400 +40,000 +42% $5.41 135,352 13 Aug 2025 Direct
transaction BCRX Common Stock Sale $595,868 -70,000 -52% $8.51 65,352 13 Aug 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCRX Automatic Stock Option Grant Options Exercise $0 -30,000 -100% $0.000000 0 13 Aug 2025 Common Stock 30,000 $2.91 Direct
transaction BCRX Automatic Stock Option Grant Options Exercise $0 -40,000 -100% $0.000000 0 13 Aug 2025 Common Stock 40,000 $5.41 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.48 to $8.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.